Edgewise Therapeutics Stock Rises on Analyst Price Target Boost
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy EWTX?
Source: Fool
- Analyst Price Target Increase: Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, resulting in a stock price increase of over 2%, significantly outperforming the S&P 500's 0.3% rise, indicating strong market confidence in the company.
- Drug Development Potential: The analyst highlighted that Edgewise has several investigational programs that could position it favorably in the biotech sector, particularly the renewed interest in EDG-7500, a drug targeting hypertrophic cardiomyopathy, which may drive future growth.
- Impact of Clinical Data Release: Last week, Edgewise published long-term data on sevasemten for muscular dystrophy, showing that Becker muscular dystrophy patients stabilized function with treatment, contrasting sharply with expected functional decline, thereby laying a solid foundation for the company's future market performance.
- Multiple Drug Development Advantage: Edgewise is not only developing one high-potential drug but also two additional drugs in the high-demand cardiovascular segment, making its diversified development strategy a standout feature in the biotech industry and attracting investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.690
Low
16.00
Averages
38.14
High
51.00
Current: 29.690
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edgewise Therapeutics Stock Rises on Analyst Price Target Boost
- Analyst Price Target Increase: Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, resulting in a stock price increase of over 2%, significantly outperforming the S&P 500's 0.3% rise, indicating strong market confidence in the company.
- Drug Development Potential: The analyst highlighted that Edgewise has several investigational programs that could position it favorably in the biotech sector, particularly the renewed interest in EDG-7500, a drug targeting hypertrophic cardiomyopathy, which may drive future growth.
- Impact of Clinical Data Release: Last week, Edgewise published long-term data on sevasemten for muscular dystrophy, showing that Becker muscular dystrophy patients stabilized function with treatment, contrasting sharply with expected functional decline, thereby laying a solid foundation for the company's future market performance.
- Multiple Drug Development Advantage: Edgewise is not only developing one high-potential drug but also two additional drugs in the high-demand cardiovascular segment, making its diversified development strategy a standout feature in the biotech industry and attracting investor interest.
See More
Analyst Raises Edgewise Price Target to $45
- Price Target Increase: Analyst Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, an increase of $11, reflecting confidence in the company's pipeline drug potential, which is expected to attract more investor interest.
- Positive Market Reaction: Following the price target increase, Edgewise's stock rose over 2% on Tuesday, significantly outperforming the S&P 500's 0.3% gain, indicating a bullish sentiment among investors towards the biotech firm.
- Pipeline Drug Potential: The analyst highlighted Edgewise's EDG-7500 drug targeting the high-demand market for hypertrophic cardiomyopathy (HCM), which could propel the company to a leading position in the biotech sector.
- Clinical Data Support: Recent long-term data from Edgewise's muscular dystrophy treatment sevasemten showed stabilization of function in Becker-type patients, contrasting sharply with expected declines from natural history data, further bolstering market confidence in its products.
See More
Edgewise Presents Becker Muscular Dystrophy Study Data at MDA Conference
- Significant Functional Stability: The MESA study demonstrated that participants treated with sevasemten maintained functional stability over 3.5 years, contrasting sharply with the expected decline from Becker natural history studies, highlighting the drug's potential efficacy and safety.
- Clinical Trial Progress: Edgewise anticipates releasing pivotal GRAND CANYON data in Q4 2026, and if results are positive, will advance sevasemten towards a marketing application, potentially becoming the first targeted therapy for Becker, addressing a significant treatment gap.
- High Participant Engagement: With 99% of eligible participants from prior sevasemten studies opting to enroll in the MESA open-label extension, this high engagement reflects strong patient recognition and trust in the drug, enhancing the reliability of the study outcomes.
- Innovative Mechanism: Sevasemten, an orally administered fast skeletal myosin inhibitor, aims to reduce muscle damage, and its unique mechanism offers new hope for treating Becker and Duchenne muscular dystrophies, potentially transforming patients' quality of life.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and strengthening the team, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Setting: Each inducement stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: Under the plan, 25% of the stock options will vest on each employee's one-year anniversary, with an additional 1/48th vesting monthly thereafter, designed to incentivize long-term retention and contribution to the company's growth.
- Company Background: Edgewise is a biopharmaceutical company focused on muscle diseases, developing novel therapeutics for muscular dystrophies and serious cardiac conditions, dedicated to improving the quality of life for patients and their families.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing employee loyalty, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Set: Each stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule stipulates that 25% of the options will vest on the one-year anniversary of each employee's start date, with an additional 1/48th vesting monthly thereafter, which is designed to improve employee retention during their tenure at the company.
- Company Background: Edgewise focuses on developing biopharmaceuticals for muscle diseases, with ongoing clinical trials for Sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, showcasing the company's deep expertise in muscle physiology.
See More
Edgewise Therapeutics Reports Q4 Results with Significant Cash Reserves
- Financial Performance: Edgewise Therapeutics reported a Q4 GAAP EPS of -$0.47, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held approximately $530.1 million in cash, cash equivalents, and marketable securities, providing significant financial flexibility for future R&D and operational needs.
- Conference Presentation: Edgewise presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially paving the way for future financing and partnership opportunities.
- Clinical Trial Progress: The company reported positive mid-stage trial data for its heart disease therapy, suggesting that despite current financial struggles, favorable clinical outcomes may set the stage for key catalysts in Q2 2026.
See More
Edgewise Therapeutics Stock Rises on Analyst Price Target Boost
- Analyst Price Target Increase: Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, resulting in a stock price increase of over 2%, significantly outperforming the S&P 500's 0.3% rise, indicating strong market confidence in the company.
- Drug Development Potential: The analyst highlighted that Edgewise has several investigational programs that could position it favorably in the biotech sector, particularly the renewed interest in EDG-7500, a drug targeting hypertrophic cardiomyopathy, which may drive future growth.
- Impact of Clinical Data Release: Last week, Edgewise published long-term data on sevasemten for muscular dystrophy, showing that Becker muscular dystrophy patients stabilized function with treatment, contrasting sharply with expected functional decline, thereby laying a solid foundation for the company's future market performance.
- Multiple Drug Development Advantage: Edgewise is not only developing one high-potential drug but also two additional drugs in the high-demand cardiovascular segment, making its diversified development strategy a standout feature in the biotech industry and attracting investor interest.
See More
Analyst Raises Edgewise Price Target to $45
- Price Target Increase: Analyst Tessa Romero from JPMorgan raised Edgewise Therapeutics' price target from $34 to $45, an increase of $11, reflecting confidence in the company's pipeline drug potential, which is expected to attract more investor interest.
- Positive Market Reaction: Following the price target increase, Edgewise's stock rose over 2% on Tuesday, significantly outperforming the S&P 500's 0.3% gain, indicating a bullish sentiment among investors towards the biotech firm.
- Pipeline Drug Potential: The analyst highlighted Edgewise's EDG-7500 drug targeting the high-demand market for hypertrophic cardiomyopathy (HCM), which could propel the company to a leading position in the biotech sector.
- Clinical Data Support: Recent long-term data from Edgewise's muscular dystrophy treatment sevasemten showed stabilization of function in Becker-type patients, contrasting sharply with expected declines from natural history data, further bolstering market confidence in its products.
See More
Edgewise Presents Becker Muscular Dystrophy Study Data at MDA Conference
- Significant Functional Stability: The MESA study demonstrated that participants treated with sevasemten maintained functional stability over 3.5 years, contrasting sharply with the expected decline from Becker natural history studies, highlighting the drug's potential efficacy and safety.
- Clinical Trial Progress: Edgewise anticipates releasing pivotal GRAND CANYON data in Q4 2026, and if results are positive, will advance sevasemten towards a marketing application, potentially becoming the first targeted therapy for Becker, addressing a significant treatment gap.
- High Participant Engagement: With 99% of eligible participants from prior sevasemten studies opting to enroll in the MESA open-label extension, this high engagement reflects strong patient recognition and trust in the drug, enhancing the reliability of the study outcomes.
- Innovative Mechanism: Sevasemten, an orally administered fast skeletal myosin inhibitor, aims to reduce muscle damage, and its unique mechanism offers new hope for treating Becker and Duchenne muscular dystrophies, potentially transforming patients' quality of life.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and strengthening the team, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Setting: Each inducement stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: Under the plan, 25% of the stock options will vest on each employee's one-year anniversary, with an additional 1/48th vesting monthly thereafter, designed to incentivize long-term retention and contribution to the company's growth.
- Company Background: Edgewise is a biopharmaceutical company focused on muscle diseases, developing novel therapeutics for muscular dystrophies and serious cardiac conditions, dedicated to improving the quality of life for patients and their families.
See More
Edgewise Grants Stock Options to New Employees
- Stock Option Grant: On February 27, 2026, Edgewise Therapeutics granted 51,000 stock options to three new non-executive employees, aimed at attracting talent and enhancing employee loyalty, in accordance with the company's 2024 Inducement Equity Incentive Plan.
- Exercise Price Set: Each stock option has an exercise price of $30.44 per share, equal to the closing price of Edgewise common stock on the grant date, ensuring alignment of employee interests with those of shareholders.
- Vesting Arrangement: The vesting schedule stipulates that 25% of the options will vest on the one-year anniversary of each employee's start date, with an additional 1/48th vesting monthly thereafter, which is designed to improve employee retention during their tenure at the company.
- Company Background: Edgewise focuses on developing biopharmaceuticals for muscle diseases, with ongoing clinical trials for Sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, showcasing the company's deep expertise in muscle physiology.
See More
Edgewise Therapeutics Reports Q4 Results with Significant Cash Reserves
- Financial Performance: Edgewise Therapeutics reported a Q4 GAAP EPS of -$0.47, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held approximately $530.1 million in cash, cash equivalents, and marketable securities, providing significant financial flexibility for future R&D and operational needs.
- Conference Presentation: Edgewise presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and potentially paving the way for future financing and partnership opportunities.
- Clinical Trial Progress: The company reported positive mid-stage trial data for its heart disease therapy, suggesting that despite current financial struggles, favorable clinical outcomes may set the stage for key catalysts in Q2 2026.
See More
